1
|
Onken B, Sedore CA, Coleman‐Hulbert AL, Hall D, Johnson E, Jones EG, Banse SA, Huynh P, Guo S, Xue J, Chen E, Harinath G, Foulger A, Chao EA, Hope J, Bhaumik D, Plummer T, Inman D, Morshead M, Guo M, Lithgow G, Phillips PC, Driscoll M. Metformin treatment of diverse Caenorhabditis species reveals the importance of genetic background in longevity and healthspan extension outcomes. Aging Cell 2022; 21:e13488. [PMID: 34837316 PMCID: PMC8761014 DOI: 10.1111/acel.13488] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 08/31/2021] [Accepted: 09/19/2021] [Indexed: 11/30/2022] Open
Abstract
Metformin, the most commonly prescribed anti‐diabetes medication, has multiple reported health benefits, including lowering the risks of cardiovascular disease and cancer, improving cognitive function with age, extending survival in diabetic patients, and, in several animal models, promoting youthful physiology and lifespan. Due to its longevity and health effects, metformin is now the focus of the first proposed clinical trial of an anti‐aging drug—the Targeting Aging with Metformin (TAME) program. Genetic variation will likely influence outcomes when studying metformin health effects in human populations. To test for metformin impact in diverse genetic backgrounds, we measured lifespan and healthspan effects of metformin treatment in three Caenorhabditis species representing genetic variability greater than that between mice and humans. We show that metformin increases median survival in three C. elegans strains, but not in C. briggsae and C. tropicalis strains. In C. briggsae, metformin either has no impact on survival or decreases lifespan. In C. tropicalis, metformin decreases median survival in a dose‐dependent manner. We show that metformin prolongs the period of youthful vigor in all C. elegans strains and in two C. briggsae strains, but that metformin has a negative impact on the locomotion of C. tropicalis strains. Our data demonstrate that metformin can be a robust promoter of healthy aging across different genetic backgrounds, but that genetic variation can determine whether metformin has positive, neutral, or negative lifespan/healthspan impact. These results underscore the importance of tailoring treatment to individuals when testing for metformin health benefits in diverse human populations.
Collapse
Affiliation(s)
- Brian Onken
- Nelson Biological Laboratories Department of Molecular Biology and Biochemistry Rutgers University Piscataway New Jersey USA
| | | | | | - David Hall
- The Buck Institute for Research on Aging Novato California USA
| | - Erik Johnson
- Institute of Ecology and Evolution University of Oregon Eugene Oregon USA
| | | | - Stephen A. Banse
- Institute of Ecology and Evolution University of Oregon Eugene Oregon USA
| | - Phu Huynh
- Nelson Biological Laboratories Department of Molecular Biology and Biochemistry Rutgers University Piscataway New Jersey USA
| | - Suzhen Guo
- Nelson Biological Laboratories Department of Molecular Biology and Biochemistry Rutgers University Piscataway New Jersey USA
| | - Jian Xue
- Nelson Biological Laboratories Department of Molecular Biology and Biochemistry Rutgers University Piscataway New Jersey USA
| | - Esteban Chen
- Nelson Biological Laboratories Department of Molecular Biology and Biochemistry Rutgers University Piscataway New Jersey USA
| | - Girish Harinath
- Nelson Biological Laboratories Department of Molecular Biology and Biochemistry Rutgers University Piscataway New Jersey USA
| | - Anna C. Foulger
- The Buck Institute for Research on Aging Novato California USA
| | | | - June Hope
- The Buck Institute for Research on Aging Novato California USA
| | - Dipa Bhaumik
- The Buck Institute for Research on Aging Novato California USA
| | - Todd Plummer
- The Buck Institute for Research on Aging Novato California USA
| | - Delaney Inman
- The Buck Institute for Research on Aging Novato California USA
| | | | - Max Guo
- Division of Aging Biology National Institute on Aging Bethesda Maryland USA
| | | | | | - Monica Driscoll
- Nelson Biological Laboratories Department of Molecular Biology and Biochemistry Rutgers University Piscataway New Jersey USA
| |
Collapse
|
2
|
Usami Y, Higuchi M, Mizuki K, Yamamoto M, Kanki M, Nakasone C, Sugimoto Y, Shibano M, Uesawa Y, Nagai J, Yoneyama H, Harusawa S. Syntheses and Glycosidase Inhibitory Activities, and in Silico Docking Studies of Pericosine E Analogs Methoxy-Substituted at C6. Mar Drugs 2020; 18:E221. [PMID: 32326065 PMCID: PMC7230162 DOI: 10.3390/md18040221] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2020] [Revised: 04/15/2020] [Accepted: 04/17/2020] [Indexed: 12/14/2022] Open
Abstract
Inspired by the significant -glucosidase inhibitory activities of (+)- and (-)-pericosine E, we herein designed and synthesized 16 analogs of these marine natural products bearing a methoxy group instead of a chlorine atom at C6. Four of these compounds exhibited moderate -glucosidase inhibitory activities, which were weaker than those of the corresponding chlorine-containing species. The four compounds could be prepared by coupling reactions utilizing the (-)-pericosine B moiety. An additional in silico docking simulation suggested that the reason of reduced activity of the C6-methoxylated analogs might be an absence of hydrogen bonding between a methoxy group with the surrounding amino acid residues in the active site in -glucosidase.
Collapse
Affiliation(s)
- Yoshihide Usami
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki, Osaka 569-1094, Japan; (M.H.); (K.M.); (M.Y.); (M.K.); (C.N.); (Y.S.); (H.Y.); (S.H.)
| | - Megumi Higuchi
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki, Osaka 569-1094, Japan; (M.H.); (K.M.); (M.Y.); (M.K.); (C.N.); (Y.S.); (H.Y.); (S.H.)
| | - Koji Mizuki
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki, Osaka 569-1094, Japan; (M.H.); (K.M.); (M.Y.); (M.K.); (C.N.); (Y.S.); (H.Y.); (S.H.)
| | - Mizuki Yamamoto
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki, Osaka 569-1094, Japan; (M.H.); (K.M.); (M.Y.); (M.K.); (C.N.); (Y.S.); (H.Y.); (S.H.)
| | - Mao Kanki
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki, Osaka 569-1094, Japan; (M.H.); (K.M.); (M.Y.); (M.K.); (C.N.); (Y.S.); (H.Y.); (S.H.)
| | - Chika Nakasone
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki, Osaka 569-1094, Japan; (M.H.); (K.M.); (M.Y.); (M.K.); (C.N.); (Y.S.); (H.Y.); (S.H.)
| | - Yuya Sugimoto
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki, Osaka 569-1094, Japan; (M.H.); (K.M.); (M.Y.); (M.K.); (C.N.); (Y.S.); (H.Y.); (S.H.)
| | - Makio Shibano
- Department of Natural Products Research, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki, Osaka 569-1094, Japan;
| | - Yoshihiro Uesawa
- Department of Medical Molecular Informatics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan; (Y.U.); (J.N.)
| | - Junko Nagai
- Department of Medical Molecular Informatics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan; (Y.U.); (J.N.)
| | - Hiroki Yoneyama
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki, Osaka 569-1094, Japan; (M.H.); (K.M.); (M.Y.); (M.K.); (C.N.); (Y.S.); (H.Y.); (S.H.)
| | - Shinya Harusawa
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki, Osaka 569-1094, Japan; (M.H.); (K.M.); (M.Y.); (M.K.); (C.N.); (Y.S.); (H.Y.); (S.H.)
| |
Collapse
|